@article{fdi:010026106,
  title = {{V}accine potential of a recombinant glutathione {S}-transferase cloned from {S}chistosoma haematobium in primates experimentally infected with an homologous challenge},
  author = {{B}oulanger, {D}. and {W}arter, {A}. and {S}ellin, {B}ertrand and {L}indner, {V}. and {P}ierce, {R}.{J}. and {C}hippaux, {J}ean-{P}hilippe and {C}apron, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{P}atas monkeys were twice immunized with a #{S}chistosoma haematobium$-derived recombinant glutathione {S}-transferase ({S}h28{GST}) then challenged with an homologous calibrated challenge. {BCG} and {F}reund's {C}omplete {A}djuvant ({FCA}) were used as adjuvants in two distinct protocols. {S}pecific {I}g{C} and {I}g{A} antibody responses were intense and homogeneous in the animals receiving {S}h28{GST} in the presence of {FCA}, whereas {BCG} could only induce moderate and heterogeneous antibody titres. {N}o significant effect on worm burdens was evidenced 36 weeks post-infection in either group of {S}h28{GST}-immunized animals compared to their matched controls receiving an irrelevant protein. {A}lthough not significant, 50% reductions in the numbers of eggs located in all tissues ({FCA} group) and in the urogenital system ({BCG} group) were noted. {M}oreover, the total number of excreted eggs was dramatically diminished by 60% and 77% in the {BCG} and {FCA} groups, respectively. {T}hese reductions reached 75% and 80% in the urines of vaccinated monkeys. {B}ladder pathology was also reduced in the animals displaying the lowest urinary egg excretions. {T}here was no clear positive or negative correlate between antibody responses and individual levels of protection. {T}aken as a whole, our results show that {S}h28{GST} was capable of significantly reducing #{S}. haematobium$ worm fecundity in experimentally infected primates. {A}lthough {FCA} induced higher levels of protection, the efficacy of {BCG} as an adjuvant appeared sufficient to justify consideration of the future application of this new formulation as a vaccine against human urogenital schistosomosis. ({R}{\'e}sum{\'e} d'auteur)},
  keywords = {{SCHISTOSOMIASE} ; {VACCINATION} ; {SINGE} ; {PARASITE} ; {ESSAI} {CLINIQUE} ; {IMMUNOLOGIE} ; {ANALYSE} {STATISTIQUE} ; {ETUDE} {EXPERIMENTALE} ; {ETUDE} {COMPARATIVE} ; {GLUTATHIONE} {S} {TRANSFERASE} ; {ANATOMOPATHOLOGIE} ; {BILHARZIOSE} {URINAIRE} ; {NIGER}},
  booktitle = {},
  journal = {{V}accine},
  volume = {17},
  numero = {},
  pages = {319--326},
  ISSN = {0264-410{X}},
  year = {1999},
  DOI = {10.1016/{S}0264-410{X}(98)00202-3},
  URL = {https://www.documentation.ird.fr/hor/fdi:010026106},
}